In 2025, we introduced a new collaborative Biosimilar Taskforce to address this potentially transformative area. The taskforce coordinates activity across the system , optimise biosimilar uptake and ...
More than 80,000 adults and teenagers across England suffering with a chronic skin condition could have their lives transformed after NICE today (Tuesday, 24 February) recommended the first licensed ...
NICE recommended rimegepant in 2023 for treating migraine and preventing episodic attacks (between 4 and 14 migraines per month), and atogepant in 2024 for preventing both episodic and chronic ...
People diagnosed with type 2 diabetes before age 40 face a higher lifetime risk of heart and kidney problems, so may benefit from adding another type of medicine called a GLP-1 receptor agonist (such ...
Nice has recommended the first disease modifying treatment for arginase 1 deficiency (ARG1-D), an ultra-rare, inherited and progressive metabolic disorder, for routine use in the NHS in England.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results